UNSPSC 51411712: Papaverine sulfate

This classification denotes a vasodilating agent and phosphodiesterase inhibitor with the molecular formula C20H21NO4.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7A476JZB2T. European Medicines Agency schedules papaverine sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14767MIG. Most nations, for tariff and trade purposes, schedule papaverine sulfate under HS 29391900. As of Q4 2014, PAPAVERINE SULFATE remains US FDA's Preferred Term for this commodity.

Papaverine sulfate bears US NLM identifiers UMLS ID C3273741 and NCI Concept Code C97985. SMILES: COC1CCC(CC1OC)CC2C3CC(C(CC3CCN2)OC)OC.OS(=O)(=O)O.

UNSPSC 51411712 Papaverine sulfate is a Commodity code that covers pharmaceutical ingredients and finished medications supplied to state and local health agencies, fire rescue services, and pharmacy benefit programs. State and local governments procure under this code primarily for emergency medical services and institutional pharmacy needs, including advanced life support medications for fire departments and generic pharmaceuticals for statewide health benefit programs. Recent solicitations show demand for specific medication formulations with stringent supply-chain compliance, expiration-date management, and regulatory documentation including Safety Data Sheets compliant with OSHA standards and FDA certification. Issuing bodies include municipal purchasing departments (city fire services), state health agencies managing pharmacy benefit programs, and multistate cooperative purchasing alliances that aggregate demand across state and local facilities. The mix reflects both direct-buy procurement by individual jurisdictions and cooperative purchasing mechanisms that serve multiple states and localities simultaneously.

Geographic activity centers on Texas, Minnesota, and Florida, with the Texas Health and Human Services Commission currently exploring direct-to-manufacturer pharmacy programs and the Minnesota Multistate Cooperative Purchasing Alliance managing a multistate RFP for generic pharmaceuticals and OTC products. The City of Tampa issued an IFB (26P00188) on April 24, 2026, for Advanced Life Support Medications to be supplied to Tampa Fire Rescue with a due date of April 8, 2026 — notably backdated, indicating a compressed or amended timeline — requiring 370 units of Labetalol HCI 100mg vials, 1,810 units of Epinephrine 1:10,000 injections, 330 units of Adenosine 6mg vials, and 1,020 units of Diltiazem 25mg vials at an estimated contract value of $40,000.00 with a Small Local Business Enterprise sheltered market designation and a 5 percent SLBE bid discount not to exceed $10,000. Minnesota's MMCAP cooperative issued an RFP (S1070000015802) due March 26, 2026, for generic multi-source pharmaceuticals and OTC products to be supplied through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC) with contract effectiveness July 1, 2026 and a two-year term. Texas HHS issued an RFI (HHS0017013) due April 3, 2026, to gather vendor capabilities for implementing a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling exploratory procurement activity that may lead to formal RFP issuance.